Epstein; Alan L.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Epstein; Alan L..The latest application filed is for "lym-1 and lym-2 antibody compositions and improved car constructs".
Company Profile
7.33.33
- Epstein; Alan L. - Los Angeles CA
- Epstein; Alan L. - Pasadena CA
- Epstein; Alan L. - La Canada CA
- Epstein; Alan L. - LaCanada CA
Patent Activity
| Patent | Date |
|---|---|
| Lym-1 And Lym-2 Antibody Compositions And Improved Car Constructs App 20220056139 - Epstein; Alan L. ; et al. | 2022-02-24 |
| Car T-cell Therapy Directed To Lhr For The Treatment Of Solid Tumors App 20210403585 - Epstein; Alan L. ; et al. | 2021-12-30 |
| Car t-cell therapy directed to LHR for the treatment of solid tumors Grant 11,136,401 - Epstein , et al. October 5, 2 | 2021-10-05 |
| Lym-1 And Lym-2 Targeted Car Cell Immunotherapy App 20210147551 - Epstein; Alan L. | 2021-05-20 |
| CD20 scFv-ELPs methods and therapeutics Grant 10,961,317 - Epstein , et al. March 30, 2 | 2021-03-30 |
| Hla-g As A Novel Target For Car T-cell Immunotherapy App 20210070864 - Epstein; Alan L. ; et al. | 2021-03-11 |
| Lym-1 and Lym-2 targeted CAR cell immunotherapy Grant 10,711,064 - Epstein | 2020-07-14 |
| CD20 scFv-ELPs METHODS AND THERAPEUTICS App 20200079868 - Epstein; Alan L. ; et al. | 2020-03-12 |
| Chimeric Antigen Receptors And Compositions And Methods Of Use Thereof App 20200016201 - Epstein; Alan L. | 2020-01-16 |
| Hla-g As A Novel Target For Car T-cell Immunotherapy App 20190119385 - Epstein; Alan L. ; et al. | 2019-04-25 |
| OX40L fusion protein for the immunotherapy of tumors of veterinary animals Grant 10,196,435 - Epstein , et al. Fe | 2019-02-05 |
| Secretory Tnt Car Cell Immunotherapy App 20180291089 - Epstein; Alan L. ; et al. | 2018-10-11 |
| Car T-cells For The Treatment Of B7-h4 Expressing Solid Tumors App 20180118831 - Epstein; Alan L. ; et al. | 2018-05-03 |
| Car T-cell Therapy Directed To Lhr For The Treatment Of Solid Tumors App 20180112003 - Epstein; Alan L. ; et al. | 2018-04-26 |
| Human myeloid derived suppressor cell cancer markers Grant 9,746,480 - Epstein , et al. August 29, 2 | 2017-08-29 |
| Cancer targeted innate immunity Grant 9,522,958 - Epstein , et al. December 20, 2 | 2016-12-20 |
| Lym-1 And Lym-2 Targeted Car Cell Immunotherapy App 20160355590 - Epstein; Alan L. | 2016-12-08 |
| CD20 scFv-ELPs METHODS AND THERAPEUTICS App 20150218280 - Epstein; Alan L. ; et al. | 2015-08-06 |
| Human Myeloid Derived Suppressor Cell Cancer Markers App 20150204887 - EPSTEIN; Alan L. ; et al. | 2015-07-23 |
| Ox40l Fusion Protein For The Immunotherapy Of Tumors Of Veterinary Animals App 20150191525 - Epstein; Alan L. ; et al. | 2015-07-09 |
| Human myeloid derived suppressor cell cancer markers Grant 8,883,497 - Epstein , et al. November 11, 2 | 2014-11-11 |
| Compositions and methods for cancer immunotherapy Grant 8,795,672 - Epstein , et al. August 5, 2 | 2014-08-05 |
| Compositions And Methods For Cancer Immunotherapy App 20140099305 - Epstein; Alan L. ; et al. | 2014-04-10 |
| Compositions and methods for cancer immunotherapy Grant 8,545,838 - Epstein , et al. October 1, 2 | 2013-10-01 |
| Human Myeloid Derived Suppressor Cell Cancer Markers App 20120276004 - Epstein; Alan L. ; et al. | 2012-11-01 |
| Cancer Targeted Innate Immunity App 20120076804 - Epstein; Alan L. ; et al. | 2012-03-29 |
| Methods of using interleukin-2 mutants with reduced toxicity Grant 8,124,066 - Epstein , et al. February 28, 2 | 2012-02-28 |
| Therapeutic Use Of Interleukin-2 Mutants App 20110091413 - Epstein; Alan L. ; et al. | 2011-04-21 |
| Therapeutic use of interleukin-2 mutants Grant 7,803,361 - Epstein , et al. September 28, 2 | 2010-09-28 |
| Interleukin-2 Mutants With Reduced Toxicity App 20090274653 - Epstein; Alan L. ; et al. | 2009-11-05 |
| Therapeutic use of interleukin-2 mutants Grant 7,514,073 - Epstein , et al. April 7, 2 | 2009-04-07 |
| Interleukin-2 mutants with reduced toxicity Grant 7,371,371 - Epstein , et al. May 13, 2 | 2008-05-13 |
| Interleukin-2 mutants with reduced toxicity App 20060292116 - Epstein; Alan L. ; et al. | 2006-12-28 |
| Targeted innate immunity App 20060135459 - Epstein; Alan L. ; et al. | 2006-06-22 |
| Polymer-bound antibody cancer therapeutic agent App 20050214286 - Epstein, Alan L. ; et al. | 2005-09-29 |
| Interleukin-2 mutants with reduced toxicity App 20050201979 - Epstein, Alan L. ; et al. | 2005-09-15 |
| Compositions and methods for cancer immunotherapy App 20040228836 - Epstein, Alan L. ; et al. | 2004-11-18 |
| Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof App 20040156824 - Epstein, Alan L. ; et al. | 2004-08-12 |
| Method for the diagnosis of neoplastic tissue comprising administering a vasopermeability enhancing peptide of human interleukin-2 Grant 6,737,064 - Epstein , et al. May 18, 2 | 2004-05-18 |
| Vasopermeability-enhancing conjugates Grant 6,696,276 - Epstein , et al. February 24, 2 | 2004-02-24 |
| Interleukin-2 mutants with reduced toxicity App 20030124678 - Epstein, Alan L. ; et al. | 2003-07-03 |
| Vasopermeability-enhancing conjugates App 20030113872 - Epstein, Alan L. ; et al. | 2003-06-19 |
| Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof App 20020164302 - Epstein, Alan L. ; et al. | 2002-11-07 |
| Vasopermeability-enhancing conjugates App 20020068328 - Epstein, Alan L. ; et al. | 2002-06-06 |
| Detection of necrotic malignant tissue and associated therapy Grant 6,071,491 - Epstein , et al. June 6, 2 | 2000-06-06 |
| Detection of necrotic malignant tissue and associated therapy Grant 6,017,514 - Epstein , et al. January 25, 2 | 2000-01-25 |
| Vasopermeability enhancing immunoconjugates Grant 6,007,817 - Epstein , et al. December 28, 1 | 1999-12-28 |
| Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof Grant 6,008,319 - Epstein , et al. December 28, 1 | 1999-12-28 |
| Antibodies with reduced net positive charge Grant 5,990,286 - Khawli , et al. November 23, 1 | 1999-11-23 |
| Detection of necrotic malignant tissue and associated therapy Grant 5,882,626 - Epstein , et al. March 16, 1 | 1999-03-16 |
| Modified antibodies Grant 5,194,594 - Khawli , et al. March 16, 1 | 1993-03-16 |
| Detection of necrotic malignant tissue and associated therapy Grant 5,019,368 - Epstein , et al. May 28, 1 | 1991-05-28 |
| Detection of necrotic malignant tissue and associated therapy Grant 4,861,581 - Epstein , et al. August 29, 1 | 1989-08-29 |
| Murine hybridoma Lym-1 and diagnostic antibody produced thereby Grant 4,724,213 - Epstein February 9, 1 | 1988-02-09 |
| Murine hybridoma Lym-2 and diagnostic antibody produced thereby Grant 4,724,212 - Epstein February 9, 1 | 1988-02-09 |
Company Registrations
| NCAGE Code | 4SH33 | EPSTEIN, ALAN L |
| CAGE Code | 4SH33 | EPSTEIN, ALAN L |
| DUNS | 800582509 | EPSTEIN, ALAN L |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 